Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.90 |
| ▸ | GAK | O14976 | 4/20 | 0.90 |
| ▸ | KDR | P35968 | 3/20 | 0.90 |
| ▸ | ILK | Q13418 | 2/20 | 0.90 |
| ▸ | FLT1 | P17948 | 2/20 | 0.90 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.90 |
| ▸ | BUB1 | O43683 | 2/20 | 0.90 |
| ▸ | STK10 | O94804 | 2/20 | 0.90 |
| ▸ | ABL1 | P00519 | 2/20 | 0.90 |
| ▸ | LCK | P06239 | 2/20 | 0.90 |
| ▸ | LYN | P07948 | 2/20 | 0.90 |
| ▸ | RET | P07949 | 2/20 | 0.90 |
| ▸ | SRC | P12931 | 2/20 | 0.90 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.90 |
| ▸ | FECH | P22830 | 2/20 | 0.90 |
| ▸ | FLT3 | P36888 | 2/20 | 0.90 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.90 |
| ▸ | PLK4 | O00444 | 1/20 | 0.90 |
| ▸ | CIT | O14578 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507409 | 1.00 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| SCHEMBL1507627 | 1.00 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| SCHEMBL2435950 | 1.00 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Hydrochloric Acid SCHEMBL1507689 | 0.99 | EGFR (0.98) | EGFRERBB2GAKKDRILK | |
| Hydrochloric Acid SCHEMBL1507491 | 0.99 | EGFR (0.98) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL29120903 | 0.95 | EGFR (0.96) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL3667407 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL8413 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL29351329 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK | |
| Erlotinib SCHEMBL30362833 | 0.95 | EGFR (1.00) | EGFRERBB2GAKKDRILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| US-11723891-B2 | Drug combinations for use in the treatment of RAS-mutant cancer | UMC UTRECHT HOLDING B.V. (NL) | 2023-08-15 | — | — | US | claimed |
| US-11692028-B2 | Map kinase pathway targets for the treatment of Marfan syndrome | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-04 | — | — | US | claimed |
| US-20230130791-A1 | A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-04-27 | — | — | US | claimed |
| US-20230119324-A1 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-04-20 | — | — | US | claimed |
| US-11612601-B1 | Targeting epidermal growth factor to treat vascular calcification | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-03-28 | — | — | US | claimed |
| EP-4117788-A1 | COMBINED INHIBITION OF EGFR AND NRF2 IN THE TREATMENT OF MALIGNANT GLIOMA | UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-01-18 | — | — | EP | claimed |
| EP-4106879-A1 | IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| EP-4106793-A1 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| US-11389434-B2 | Methods and pharmaceutical compositions for the treatment of mast cell diseases | INSERM (FR) | 2022-07-19 | — | — | US | claimed |
| US-20220218682-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-14 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| US-20220079935-A1 | COMPOUNDS AND TREATMENTS THAT ENHANCE ENTERIC NERVOUS SYSTEM FUNCTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-03-17 | — | — | US | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-215643385-U | Device for direct drug infusion | 基因泰克股份有限公司 | 2022-01-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079935-A1 | COMPOUNDS AND TREATMENTS THAT ENHANCE ENTERIC NERVOUS SYSTEM FUNCTION | NTRK2, BDNF, NTSR2 | EGFR 1010/4885ERBB2 630/4885GAK 1831/4885 |
| US-11389434-B2 | Methods and pharmaceutical compositions for the treatment of mast cell diseases | KIT, SHH, CMA1 | EGFR 464/4885ERBB2 560/4885GAK 1074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.